Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
| Autor: | Haag, G.M., Zoernig, I., Hassel, J.C., Halama, N., Dick, J., Lang, N., Podola, L., Funk, J., Ziegelmeier, C., Juenger, S., Bucur, M., Umansky, L., Falk, C.S., Freitag, A., Karapanagiotou-Schenkel, I., Beckhove, P., Enk, A., Jaeger, D. |
|---|---|
| Zdroj: | In European Journal of Cancer February 2018 90:122-129 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect